RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Negative 94.6%

Neg 94.6% Neu 0% Pos 0%

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $35 to $30.